Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis
Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis
复制标题
DOI：
10.2217/cer-2019-0029
复制
发表时间：
2019-08-01
影响因子：
2.1
通讯作者：
Cortijo, Julio
中科院分区：
文献类型：
--
作者：
Aguilar-Serra, Javier;Gimeno-Ballester, Vicente;Cortijo, Julio
Aim: Osimertinib improves progression-free survival in first-line EGFR mutation-positive non-small-cell lung cancer. Materials & methods: A Markov cohort model including costs, utilities and disutilities, was conducted to estimate quality-adjusted life-year (QALY) and incremental cost-effectiveness ratio when treating with osimertinib versus standard first-line tyrosine kinase inhibitors (TKIs). Results: Osimertinib presented higher QALYs (0.61) compared with standard EGFR-TKIs (0.42). Osimertinib costs were (sic)83,258.99, in comparison with (sic)29,209.45 for the standard EGFR-TKIs. An incremental cost-effectiveness ratio of (sic)273,895.36/QALY was obtained for osimertinib. Conclusion: Osimertinib was more effective in terms of QALYs gained than comparators (erlotinib-gefitinib). However, to obtain a cost-effectiveness alternative, a discount greater than 60% in osimertinib acquisition cost is required.
